Onconova Therapeutics, Inc. (ONTX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Onconova Therapeutics, Inc. (ONTX) trades at $18.48 with AI Score 44/100 (Grade C). Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ONTX: ONTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ONTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ONTX: 1/3 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Onconova Therapeutics, Inc. (ONTX) Healthcare & Pipeline Overview
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel cancer therapies, including narazaciclib and rigosertib. These targeted kinase inhibitors are in Phase I and Phase I/IIa clinical trials, positioning Onconova in the competitive oncology therapeutics market.
What Is the Investment Thesis for ONTX?
Onconova Therapeutics presents a high-risk, high-reward investment profile characteristic of clinical-stage biopharmaceutical companies. The primary value drivers are the clinical advancements of narazaciclib and rigosertib. Successful progression through clinical trials and eventual FDA approval could lead to significant revenue generation. Key catalysts include the Phase I data readout for narazaciclib in solid tumors and hematological malignancies, and the Phase I/IIa results for rigosertib in combination with a PD-1 inhibitor for non-small cell lung cancer. However, the company's negative profit margin of -326.2% and reliance on external funding pose significant risks. Investment hinges on positive clinical trial outcomes and the ability to secure additional financing.
Based on FMP financials and quantitative analysis
ONTX Key Highlights
Market capitalization of $0.02 billion reflects the company's early stage and speculative nature.
- Gross margin of 99.9% indicates strong potential profitability upon successful commercialization of its drug candidates.
- P/E ratio of -1.38 reflects the company's current lack of profitability.
- Beta of 1.35 suggests higher volatility compared to the overall market.
- Two clinical-stage programs, narazaciclib and rigosertib, represent the core value drivers for the company.
Who Are ONTX's Competitors?
ONTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CSCI COSCIENS Biopharma Inc. | $2.72 | +0.00% | $8.57M | 63 |
| DOMH Dominari Holdings Inc. | $2.71 | +5.86% | $61.3M | — |
| ELEV ELEV | $0.36 | -2.12% | $21.6M | 47 |
| LSB LakeShore Biopharma Co., Ltd | $0.63 | +0.00% | $25.8M | 46 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ONTX's Key Strengths?
Proprietary drug candidates in clinical development.
- Experienced management team with expertise in oncology.
- Strategic partnerships with pharmaceutical companies.
- Strong intellectual property portfolio.
What Are ONTX's Weaknesses?
Limited financial resources.
- Dependence on clinical trial outcomes.
- High cash burn rate.
- Lack of commercialized products.
What Could Drive ONTX Stock Higher?
Phase I data readout for narazaciclib in solid tumors and hematological malignancies.
- Phase I/IIa results for rigosertib in combination with a PD-1 inhibitor for non-small cell lung cancer.
- Enrollment and progression of patients in clinical trials.
- Expansion of strategic partnerships and collaborations.
What Are the Key Risks for ONTX?
Clinical trial failures or delays.
- Regulatory hurdles and rejection of drug candidates.
- Competition from established pharmaceutical companies.
- Dependence on external funding and potential dilution of shareholders.
- Patent expirations and loss of exclusivity.
What Are the Growth Opportunities for ONTX?
- Expansion into New Therapeutic Areas: Onconova has the opportunity to expand its pipeline beyond its current focus on hematological malignancies and solid tumors. Exploring new therapeutic areas within oncology, such as rare cancers or specific genetic mutations, could unlock new market opportunities and diversify the company's risk profile. This expansion could involve in-licensing new drug candidates or developing novel therapies internally. The timeline for this growth opportunity is dependent on research and development efforts, but could materialize within the next 3-5 years.
- Strategic Partnerships and Collaborations: Onconova can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its drug candidates. Partnering with larger pharmaceutical companies or research institutions can provide access to funding, expertise, and resources. These collaborations can also facilitate entry into new geographic markets and expand the company's reach. Successful partnerships could lead to accelerated clinical trial timelines and increased market penetration within the next 2-3 years.
- Advancement of Rigosertib for COVID-19: Onconova's preclinical program evaluating IV/oral rigosertib for the treatment of COVID-19 represents a potential growth opportunity. While the COVID-19 pandemic has subsided, there remains a need for effective antiviral therapies, particularly for immunocompromised individuals. Positive preclinical data and subsequent clinical trials could position rigosertib as a valuable treatment option. The timeline for this growth opportunity is dependent on clinical trial results and regulatory approvals, but could potentially yield results within the next 1-2 years.
- Commercialization of Narazaciclib: The successful commercialization of narazaciclib represents a significant growth opportunity for Onconova. Upon completion of Phase I trials and potential FDA approval, narazaciclib could generate substantial revenue as a targeted therapy for solid tumors and hematological malignancies. Effective marketing and distribution strategies will be crucial to capturing market share and maximizing the drug's commercial potential. This growth opportunity is contingent on positive clinical trial outcomes and regulatory approvals, with a potential timeline of 3-5 years.
- Geographic Expansion: Onconova can expand its geographic reach by entering new markets outside of the United States. Partnering with international distributors or establishing a presence in key regions, such as Europe or Asia, could significantly increase the company's revenue potential. This expansion would require careful consideration of regulatory requirements, market dynamics, and competitive landscape. The timeline for geographic expansion could vary depending on the specific market, but could be initiated within the next 2-3 years.
What Are ONTX's Competitive Advantages?
- Proprietary drug candidates in clinical development.
- Intellectual property protection through patents.
- Established partnerships with pharmaceutical companies.
- Expertise in oncology drug development.
What Does ONTX Do?
Onconova Therapeutics, Inc., established in 1998 and headquartered in Newtown, Pennsylvania, is a biopharmaceutical company dedicated to discovering and developing innovative therapies for cancer treatment. The company focuses on addressing unmet medical needs in oncology through its clinical-stage programs. Onconova's pipeline features two primary clinical-stage assets: narazaciclib (ON 123300) and rigosertib. Narazaciclib is a multi-targeted kinase inhibitor currently in Phase I clinical trials for solid tumors and hematological malignancies, both as a single agent and in combination with other anti-cancer therapies. Rigosertib, available in oral form, is being evaluated in a Phase I/IIa study in combination with a PD-1 inhibitor for the treatment of progressive K-Ras mutated non-small cell lung cancer. Additionally, Onconova is exploring rigosertib monotherapy in a Phase Ib/II ISS study for advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. The company also has a preclinical program evaluating IV/oral rigosertib for the treatment of COVID-19. Onconova has established strategic partnerships to support the development and commercialization of its therapies, including license agreements with SymBio Pharmaceuticals Limited, Pint International SA, and HanX Biopharmaceuticals, Inc.
What Products and Services Does ONTX Offer?
- Develop novel products to treat cancer.
- Focus on clinical-stage programs.
- Develop multi-targeted kinase inhibitors.
- Conduct Phase I studies for solid tumors and hematological malignancies.
- Develop oral rigosertib in combination with PD-1 inhibitors for non-small cell lung cancer.
- Develop rigosertib monotherapy for advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa.
- Conduct preclinical programs for IV/oral rigosertib for COVID-19.
How Does ONTX Make Money?
- Discovering and developing novel cancer therapies.
- Out-licensing or partnering to commercialize developed therapies.
- Generating revenue through milestone payments and royalties from partnerships.
- Securing funding through equity offerings and strategic collaborations.
What Industry Does ONTX Operate In?
Onconova operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high failure rates. The oncology therapeutics market is experiencing substantial growth, driven by an aging population and advancements in personalized medicine. Onconova's focus on targeted kinase inhibitors and combination therapies aligns with current market trends. Competitors like ATON, CSCI, DOMH, ELEV, and LSB are also vying for market share in the oncology space, emphasizing the need for Onconova to demonstrate clinical efficacy and secure regulatory approvals.
Who Are ONTX's Key Customers?
- Patients with cancer.
- Hospitals and oncology clinics.
- Pharmaceutical companies through licensing agreements.
- Research institutions through collaborations.
Forward Outlook
Wall Street analysts project Onconova Therapeutics, Inc. revenue of about $300K for fiscal 2026, with EPS near $-0.81.
Key Financial Metrics
Return on equity for Onconova Therapeutics, Inc. stands at 489.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -68.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.43 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -160.9%, the inverse of the P/E and a quick read on earnings relative to price.
ONTX Valuation & Market Position
Relative to its peer group, ONTX's quantitative score of 44/100 is below the peer average of 57/100.
ONTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's potential, indicating that key stakeholders believe in future growth.
- Community sentiment has shifted positively, with discussions highlighting optimism around upcoming clinical trial results.
- There is increasing interest in Onconova's innovative therapies, particularly in oncology, which could position them well in a growing market.
- Recent partnerships and collaborations have sparked excitement, suggesting that the company is making strategic moves to enhance its pipeline.
Bear Case
- Concerns remain about the company's cash runway, raising questions about its ability to sustain operations without additional funding.
- Social sentiment has shown some skepticism regarding the timelines of clinical trials, with some community members expressing doubts about meeting expectations.
- Market perception is cautious due to past volatility in stock performance, leading some investors to adopt a wait-and-see approach.
- Increased competition in the oncology space could pose challenges for Onconova, potentially impacting its market share and growth prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ONTX Latest News
No recent news available for ONTX.
ONTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ONTX.
Price Targets
Wall Street price target analysis for ONTX.
ONTX MoonshotScore
What does this score mean?
The MoonshotScore rates ONTX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Steven M. Fruchtman
CEO
Steven M. Fruchtman serves as the CEO of Onconova Therapeutics, bringing extensive experience in hematology and oncology. Prior to joining Onconova, he held leadership positions at numerous pharmaceutical companies, guiding clinical development programs and commercialization strategies. His background includes significant contributions to the development and approval of several cancer therapies. Fruchtman's expertise spans clinical research, regulatory affairs, and business development, making him well-suited to lead Onconova through its clinical development milestones.
Track Record: Under Steven M. Fruchtman's leadership, Onconova has focused on advancing its clinical-stage programs, particularly narazaciclib and rigosertib. He has overseen the initiation and progression of clinical trials, secured strategic partnerships, and managed the company's financial resources. Fruchtman's strategic decisions have been instrumental in positioning Onconova for potential success in the competitive oncology market.
Onconova Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for ONTX?
ONTX holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Their pipeline includes narazaciclib and rigosertib, targeting solid tumors …
What does Onconova Therapeutics, Inc. do?
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of cancer. The company's pipeline includes two clinical-stage programs: narazaciclib, a multi-targeted kinase inhibitor in Phase I trials for solid tumors and hematological malignancies, and rigosertib, being evaluated in Phase I/IIa trials for non-small cell lung cancer.
What do analysts say about ONTX stock?
Analyst coverage of ONTX stock is limited due to the company's small market capitalization and early-stage clinical development. However, analysts generally view Onconova as a high-risk, high-reward investment opportunity. The potential for significant returns is tied to the successful advancement of narazaciclib and rigosertib through clinical trials and eventual FDA approval.
What are the main risks for ONTX?
Onconova faces several key risks inherent to clinical-stage biopharmaceutical companies. Clinical trial failures represent a significant risk, as negative results could halt the development of drug candidates and significantly impact the company's value. Regulatory hurdles and potential rejection of drug candidates by the FDA also pose a threat.
What are the key factors to evaluate for ONTX?
Onconova Therapeutics, Inc. (ONTX) holds an AI score of 44/100 (low). Onconova Therapeutics presents a high-risk, high-reward investment profile characteristic of clinical-stage biopharmaceutical companies. Not financial advice.
How frequently does ONTX data refresh on this page?
ONTX's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ONTX's recent stock price performance?
Onconova Therapeutics, Inc. (ONTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidates in clinical development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ONTX overvalued or undervalued right now?
Onconova Therapeutics, Inc. (ONTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ONTX before investing?
Before investing in Onconova Therapeutics, Inc. (ONTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.